scholarly journals DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Andrea Mathe ◽  
Michelle Wong-Brown ◽  
Warwick J. Locke ◽  
Clare Stirzaker ◽  
Stephen G. Braye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Lymph Node ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Methylation Profile ◽  
Node Negative ◽  
Node Positive ◽  
Dna Methylation Profile ◽  
Lymph Node Positive

scholarly journals Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients

Glycobiology ◽  
2010 ◽  
Vol 20 (10) ◽  
pp. 1283-1288 ◽  
Author(s):  
A. Pierce ◽  
R. Saldova ◽  
U. M. Abd Hamid ◽  
J. L. Abrahams ◽  
E. W. McDermott ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Positive ◽  
Node Negative Breast Cancer ◽  
Lymph Node Positive

scholarly journals Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy

Breast Care ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. 425-433 ◽  
Author(s):  
Manfred Schmitt ◽  
Olaf G. Wilhelm ◽  
Aurelia Noske ◽  
Gabriele Schricker ◽  
Rudolph Napieralski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Lymph Node ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Lymph Node Positive ◽  
Methylation Ratio ◽  
Positive Breast Cancer

Background: Breast cancer patients at high risk for recurrence are treated with anthracycline-based chemotherapy, but not all patients do equally benefit from such a regimen. To further improve therapy decision-making, biomarkers predicting outcome are of high unmet medical need. Methods: The percent DNA methylation ratio (PMR) of the promoter gene coding for the Paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time polymerase chain reaction (PCR) test. The multicenter study was conducted in routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue from 205 lymph node-positive breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Results: The cut-off for the PITX2 methylation status (PMR = 12) was confirmed in a randomly selected cohort (n = 60) and validated (n = 145) prospectively with disease-free survival (DFS) at the 10-year follow-up. DFS was significantly different between the PMR ≤ 12 versus the PMR > 12 group with a hazard ratio (HR) of 2.74 (p < 0.001) in the validation cohort and also for the patient subgroup treated additionally with endocrine therapy (HR 2.47; p = 0.001). Conclusions: Early-stage lymph node-positive breast cancer patients with low PITX2 methylation do benefit from adjuvant anthracycline-based chemotherapy. Patients with a high PITX2 DNA methylation ratio, approximately 30%, show poor outcome and should thus be considered for alternative chemotherapy regimens.

Sign in / Sign up

Export Citation Format

Share Document